|Full HTA submission received from Applicant
|Carfilzomib (in combination with daratumumab and dexamethasone)
|In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with daratumumab and dexamethasone compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant
|Full submission received from Applicant